Martinez Bueno A, Molina MA, Fielding A, et al. Disruptive mutations in TP53 associate with survival benefit in a PARPi trial in ovarian cancer. ESMO 2017, abstract LBA42.
Adnexcystes en -tumoren bij jonge meisjes en vrouwen
aug 2018 | Gynaecologische oncologie